Dosage Comparison of Snake Anti-venom on Coagulopathy
Authors
Abstract:
This study was done to determine whether high or low dose of anti-snake venom (ASV) is better in coagulopathy in victims of envenoming by vipers. This retrospective study was conducted on the 154 patients (Mean age ± SD, Range) of viper snake bites who were referred to the emergency ward of Razi Hospital, Ahvaz, Iran over 2 years period (2004 - 2006). According to the treatment dosage the patients were divided in two groups include group 1 (78 cases), low dose regimen and group 2 (76 cases), high dose one. In group 1, the treatment was performed by administration of 4 to 6 vials of ASV through intravenous infusion. In group 2, the patients were given 5 to 10 vials of ASV as an initial dose. In low dose regimen, the number of received packed red blood cell was higher (14 vs. 3) in comparison with high dose group. The number of ASV vials the patients received was 5.5and 21.06 in group 1 and 2, respectively (5.5 ± 1.7 vs. 21.06 ± 10.89; p < 0.01). The difference in frequency of coagulopathy complications, and need for using packed red blood cell were statistically significant (96.2% and 17.9% in group 1 vs. 34.2% and 3.9% in group 2, p < 0.01). It seems that cautious usage of high dose of ASV (10 - 20 vials) without very special concerns about the cost, dose, and without hazardous side effects is essential for the routine management of sever snake envenoming.
similar resources
dosage comparison of snake anti-venom on coagulopathy
this study was done to determine whether high or low dose of anti-snake venom (asv) is better in coagulopathy in victims of envenoming by vipers. this retrospective study was conducted on the 154 patients (mean age ± sd, range) of viper snake bites who were referred to the emergency ward of razi hospital, ahvaz, iran over 2 years period (2004 - 2006). according to the treatment dosage the patie...
full textDosage Comparison of Snake Anti-Venomon Coagulopathy
This study was done to determine whether high or low dose ofanti-snake venom (ASV) is better incoagulopathy invictims of envenoming by vipers. This retrospective study was conducted on the 154 patients (Mean age ± SD, Range) of viper snake bites who were referred to the emergency ward of Razi Hospital, Ahvaz, Iran over 2 years period (2004-2006).According to the treatment dosage the patients we...
full textSnake Venom, Anti-snake Venom & Potential of Snake Venom
Many active secretions produced by animals have been employed in the development of new drugs to treat diseases such as hypertension and cancer. Snake venom toxins contributed significantly to the treatment of many medical conditions. Venomous snakes have a bad reputation and rightly so because of their often deadly bites. But what makes a snake’s bite so deadly is the venom. Of the 3000 snake ...
full textSnake venom proteins and coagulopathy caused by snakebite
Snakebite affects around 3 or 4 million humans annually leading to more than 100,000 deaths. Coagulopathy is one of the significant causes of both morbidity and mortality in these patients. Accordingly, it is of utmost importance to diagnose and treat coagulation disorder due to bites; in addition, it is accompanied by various clinical aspects, such as pre-coagulation, fibrinogen coagulation ti...
full textAnti-cancer and anti-bacterial effects of crude venom of Pseudocerastes persicus snake
Introduction: Antibiotic resistance has been reported as one of the world's most critical public health problems. Recent investigations have demonstrated that venom of some species of snakes have antimicrobial and anticancer activities. In this study, we investigated the antibacterial and anticancer effects of Persian horned viper venom. Antibacterial activity was examined on Escherichia coli,...
full textMy Resources
Journal title
volume 13 issue 1
pages 283- 289
publication date 2014-01-01
By following a journal you will be notified via email when a new issue of this journal is published.
Hosted on Doprax cloud platform doprax.com
copyright © 2015-2023